XML 46 R35.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Schedule of Revenues by Product
“Product revenues, net” consisted of the following:
Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
(in millions)
TRIKAFTA/KAFTRIO$2,653.6 $2,585.0 $7,740.2 $7,517.8 
ALYFTREK247.0 — 457.7 — 
Other product revenues175.8 186.9 582.7 590.3 
Total product revenues, net$3,076.4 $2,771.9 $8,780.6 $8,108.1 
Schedule of Product Revenues by Geographic Location
“Product revenues, net” by geographic region, based on the location of the customer, consisted of the following:
Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
(in millions)
United States$1,976.3 $1,713.5 $5,457.3 $4,847.7 
Outside of the United States
Europe836.9 847.7 2,574.4 2,621.9 
Other
263.2 210.7 748.9 638.5 
Total product revenues outside of the United States1,100.1 1,058.4 3,323.3 3,260.4 
Total product revenues, net
$3,076.4 $2,771.9 $8,780.6 $8,108.1 
Schedule of Significant Segment Expenses
Significant segment expenses are set forth in the following table:
Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
(in millions)
Total revenues$3,076.4 $2,771.9 $8,811.3 $8,108.1 
Costs and expenses:
Cost of sales - products139.6 131.6 410.7 363.9 
Cost of sales - royalty275.2 261.0 774.6 743.2 
Research expenses210.0 193.8 625.4 597.2 
Development expenses767.7 682.1 2,310.4 2,034.4 
Acquired in-process research and development expenses54.5 15.0 76.5 4,540.9 
Selling and other commercial expenses278.3 216.9 784.0 604.9 
General and administrative expenses166.8 154.9 482.1 481.8 
Intangible asset impairment charge— — 379.0 — 
Interest income(125.7)(132.2)(369.0)(469.9)
Other segment items (1)
11.2 24.7 25.4 99.7 
Provision for income taxes215.9 178.7 550.1 560.6 
Net income (loss)$1,082.9 $1,045.4 $2,762.1 $(1,448.6)
(1)Other segment items included in “Net income (loss)” primarily include changes in the fair value of contingent consideration, interest expense and changes in the fair value of equity investments.